| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marta Bolós, Juan Ramón Perea, Jesús Avil. Alzheimer's disease as an inflammatory disease. Biomolecular concepts. vol 8. issue 1. 2017-03-20. PMID:28231054. |
alzheimer's disease (ad) is a neurodegenerative condition characterized by the formation of amyloid-β plaques, aggregated and hyperphosphorylated tau protein, activated microglia and neuronal cell death, ultimately leading to progressive dementia. |
2017-03-20 |
2023-08-13 |
Not clear |
| Shifeng Chu, Shaolin Liu, Wenzhen Duan, Yong Cheng, Xueying Jiang, Chuanjiang Zhu, Kang Tang, Runsheng Wang, Lin Xu, Xiaoying Wang, Xiaoming Yu, Kemei Wu, Yan Wang, Muzou Wang, Huiyong Huang, Juntian Zhan. The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect. Pharmacology & therapeutics. vol 162. 2017-03-17. PMID:26812265. |
furthermore, (-)-clau suppresses the pathogenesis of alzheimer's disease by inhibiting multiple etiological processes: (1) beta amyloid protein-induced intracellular ca(2+) overload and apoptosis and (2) tau hyperphosphorylation and neurodegeneration. |
2017-03-17 |
2023-08-13 |
human |
| Bianca Hutter-Schmid, Christian Humpe. Alpha-Smooth Muscle Actin mRNA and Protein Are Increased in Isolated Brain Vessel Extracts of Alzheimer Mice. Pharmacology. vol 98. issue 5-6. 2017-03-16. PMID:27463512. |
alzheimer's disease (ad) is a severe neurodegenerative disorder of the brain, characterized by extracellular beta-amyloid (aβ) plaques, intracellular tau pathology, neurodegeneration and inflammation. |
2017-03-16 |
2023-08-13 |
mouse |
| Michelle M Miller-Thomas, Adam L Sipe, Tammie L S Benzinger, Jonathan McConathy, Sarah Connolly, Katherine E Schwety. Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics : a review publication of the Radiological Society of North America, Inc. vol 36. issue 4. 2017-03-14. PMID:27399239. |
targeted molecular imaging shows pathologic accumulation of aβ and tau protein, and fluorine 18 fluorodeoxyglucose positron emission tomography and anatomic imaging allow differentiation of typical patterns of neuronal dysfunction and loss in patients with alzheimer disease from those seen in patients with other types of dementia. |
2017-03-14 |
2023-08-13 |
Not clear |
| Xia-Chun Li, Yu Hu, Zhi-hao Wang, Yu Luo, Yao Zhang, Xiu-Ping Liu, Qiong Feng, Qun Wang, Keqiang Ye, Gong-Ping Liu, Jian-Zhi Wan. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Scientific reports. vol 6. 2017-03-07. PMID:27099072. |
intracellular accumulation of tau protein is hallmark of sporadic alzheimer's disease (ad), however, the cellular mechanism whereby tau accumulation causes neurodegeneration is poorly understood. |
2017-03-07 |
2023-08-13 |
mouse |
| Yingying Wu, Ningning Teng, Sen L. Effects of macromolecular crowding and osmolyte on human Tau fibrillation. International journal of biological macromolecules. vol 90. 2017-03-06. PMID:26683879. |
tau fibrillation is reported to be involved in neurodegenerative disorders, such as alzheimer's disease, in which the natural environment is very crowded in the cells. |
2017-03-06 |
2023-08-13 |
human |
| Sergej Schwagerus, Oliver Reimann, Clement Despres, Caroline Smet-Nocca, Christian P R Hackenberge. Semi-synthesis of a tag-free O-GlcNAcylated tau protein by sequential chemoselective ligation. Journal of peptide science : an official publication of the European Peptide Society. vol 22. issue 5. 2017-03-03. PMID:27071766. |
we thus provide a synthetic route to obtain a homogenous tag-free o-glcnacylated tau protein that can further help to elucidate the significance of posttranslational modification on the tau protein and pave the way for evaluating possible drug targets in alzheimer's disease. |
2017-03-03 |
2023-08-13 |
Not clear |
| Liqin Qi, Linfang Ke, Xiaohong Liu, Lianming Liao, Sujie Ke, Xiaoying Liu, Yanping Wang, Xiaowei Lin, Yu Zhou, Lijuan Wu, Zhou Chen, Libin Li. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. European journal of pharmacology. vol 783. 2017-03-03. PMID:27131827. |
subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model. |
2017-03-03 |
2023-08-13 |
mouse |
| M Dani, D J Brooks, P Ediso. Tau imaging in neurodegenerative diseases. European journal of nuclear medicine and molecular imaging. vol 43. issue 6. 2017-02-27. PMID:26572762. |
aggregated tau protein is a major neuropathological substrate central to the pathophysiology of neurodegenerative diseases such as alzheimer's disease (ad), frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration and chronic traumatic encephalopathy. |
2017-02-27 |
2023-08-13 |
Not clear |
| Lifeng Qiu, Gandi Ng, Eng King Tan, Ping Liao, Nagaendran Kandiah, Li Zen. Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice. Scientific reports. vol 6. 2017-02-27. PMID:27050297. |
chronic cerebral hypoperfusion enhances tau hyperphosphorylation and reduces autophagy in alzheimer's disease mice. |
2017-02-27 |
2023-08-13 |
mouse |
| Niels Kruse, Michael G Schlossmacher, Walter J Schulz-Schaeffer, Eugeen Vanmechelen, Hugo Vanderstichele, Omar M El-Agnaf, Brit Mollenhaue. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PloS one. vol 11. issue 4. 2017-02-27. PMID:27116005. |
the quantification of four distinct proteins (α-synuclein, β-amyloid1-42, dj-1, and total tau) in cerebrospinal fluid (csf) has been proposed as a laboratory-based platform for the diagnosis of parkinson's disease (pd) and alzheimer's disease (ad). |
2017-02-27 |
2023-08-13 |
human |
| Konstantinos Chiotis, Laure Saint-Aubert, Irina Savitcheva, Vesna Jelic, Pia Andersen, My Jonasson, Jonas Eriksson, Mark Lubberink, Ove Almkvist, Anders Wall, Gunnar Antoni, Agneta Nordber. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. European journal of nuclear medicine and molecular imaging. vol 43. issue 9. 2017-02-24. PMID:26996778. |
imaging in-vivo tau pathology in alzheimer's disease with thk5317 pet in a multimodal paradigm. |
2017-02-24 |
2023-08-13 |
Not clear |
| Dema Najem, Michelle Bamji-Mirza, Ze Yang, Wandong Zhan. Aβ-Induced Insulin Resistance and the Effects of Insulin on the Cholesterol Synthesis Pathway and Aβ Secretion in Neural Cells. Neuroscience bulletin. vol 32. issue 3. 2017-02-24. PMID:27207326. |
alzheimer's disease (ad) is characterized by amyloid-β (aβ) toxicity, tau pathology, insulin resistance, neuroinflammation, and dysregulation of cholesterol homeostasis, all of which play roles in neurodegeneration. |
2017-02-24 |
2023-08-13 |
human |
| Claire Roubaud Baudron, Christine Varon, Francis Mégraud, Nathalie Salle. [Alzheimer's disease and Helicobacter pylori infection: a possible link?]. Geriatrie et psychologie neuropsychiatrie du vieillissement. vol 14. issue 1. 2017-02-23. PMID:27005340. |
alzheimer's disease (ad) is associated with aß peptide and tau protein deposits, but the initial process inducing the disease and ultimately neurodegeneration has not yet been elucidated. |
2017-02-23 |
2023-08-13 |
mouse |
| Natarajan Suganthy, Kasi Pandima Devi, Seyed Fazel Nabavi, Nady Braidy, Seyed Mohammad Nabav. Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 84. 2017-02-13. PMID:27756054. |
several in vitro and in vivo studies have also shown that quercetin destabilizes and enhances the clearance of abnormal protein such as beta- amyloid peptide and hyperphosphorlyated tau, the key pathological hallmarks of alzheimer's disease. |
2017-02-13 |
2023-08-13 |
Not clear |
| Myuri Ruthirakuhan, Nathan Herrmann, Ivonne Suridjan, Eleenor H Abraham, Ilan Farber, Krista L Lanctô. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. Expert opinion on pharmacotherapy. vol 17. issue 18. 2017-02-13. PMID:27825018. |
keywords and search criteria included: phase 2, or 3 trials related to alzheimer's disease, mild cognitive impairment, amyloid-beta and tau. |
2017-02-13 |
2023-08-13 |
Not clear |
| Francesco Panza, Vincenzo Solfrizzi, Davide Seripa, Bruno P Imbimbo, Madia Lozupone, Andrea Santamato, Chiara Zecca, Maria Rosaria Barulli, Antonello Bellomo, Alberto Pilotto, Antonio Daniele, Antonio Greco, Giancarlo Logroscin. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. BioMed research international. vol 2016. 2017-02-10. PMID:27429978. |
the failure of several phase ii/iii clinical trials in alzheimer's disease (ad) with drugs targeting β-amyloid accumulation in the brain fuelled an increasing interest in alternative treatments against tau pathology, including approaches targeting tau phosphatases/kinases, active and passive immunization, and anti-tau aggregation. |
2017-02-10 |
2023-08-13 |
Not clear |
| b' Lucilla Parnetti, Paolo Eusebi, Alberto Lle\\xc3\\xb. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer\'s and Parkinson\'s Diseases. Frontiers of neurology and neuroscience. vol 39. 2017-02-10. PMID:27463974.' |
in alzheimer's disease (ad), three csf biomarkers (aβ42, total tau, and phosphorylated tau) are used in clinical practice to support the diagnosis in the prodromal stages of the disease. |
2017-02-10 |
2023-08-13 |
Not clear |
| Yu Hu, Xia-Chun Li, Zhi-hao Wang, Yu Luo, Xiangnan Zhang, Xiu-Ping Liu, Qiong Feng, Qun Wang, Zhenyu Yue, Zhong Chen, Keqiang Ye, Jian-Zhi Wang, Gong-Ping Li. Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget. vol 7. issue 14. 2017-02-09. PMID:26943044. |
intracellular accumulation of wild type tau is a hallmark of sporadic alzheimer's disease (ad). |
2017-02-09 |
2023-08-13 |
mouse |
| Carmen Inda, Alexander Bolaender, Tai Wang, Srinivasa R Gandu, John Kore. Stressing Out Hsp90 in Neurotoxic Proteinopathies. Current topics in medicinal chemistry. vol 16. issue 25. 2017-02-09. PMID:27072699. |
for reasons not yet elucidated, hsp90 and the molecular chaperones interact with, but do not degrade, these toxic proteins resulting in the pathogenic accumulation of proteins such as tau, in alzheimer's disease, and α-synuclein, in parkinson's disease. |
2017-02-09 |
2023-08-13 |
Not clear |